572924-00-6 Usage
Description
(S)-2-Cyclopentyloxycarbonylamino-3,3-dimethyl-butyric acid is a chemical compound that belongs to the class of organic compounds known as amino acids and derivatives. It is a derivative of valine, an essential amino acid that cannot be synthesized by the body and must be obtained through the diet. (S)-2-CYCLOPENTYLOXYCARBONYLAMINO-3,3-DIMETHYL-BUTYRIC ACID contains a cyclopentyl group, a carbonyl group, and an amino group, which are all important functional groups in organic chemistry. The presence of these functional groups gives this compound various biological and chemical properties that make it important for various industrial and pharmaceutical applications. Overall, (S)-2-Cyclopentyloxycarbonylamino-3,3-dimethyl-butyric acid is a versatile compound with potential uses in many different fields.
Uses
Used in Pharmaceutical Industry:
(S)-2-Cyclopentyloxycarbonylamino-3,3-dimethyl-butyric acid is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique structure and functional groups make it a valuable building block in the development of new medications.
Used in Chemical Research:
(S)-2-Cyclopentyloxycarbonylamino-3,3-dimethyl-butyric acid is used as a research compound in the field of organic chemistry. Its various functional groups allow for the study of different chemical reactions and the development of new synthetic methods.
Used in Biochemical Studies:
(S)-2-Cyclopentyloxycarbonylamino-3,3-dimethyl-butyric acid is used in biochemical research to investigate the role of amino acids and their derivatives in biological systems. Its unique structure can provide insights into the mechanisms of various biological processes.
Used in Industrial Applications:
(S)-2-Cyclopentyloxycarbonylamino-3,3-dimethyl-butyric acid is used in various industrial applications due to its versatile chemical properties. Its functional groups can be utilized in the synthesis of different types of compounds, making it a valuable component in the production of various products.
Check Digit Verification of cas no
The CAS Registry Mumber 572924-00-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,7,2,9,2 and 4 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 572924-00:
(8*5)+(7*7)+(6*2)+(5*9)+(4*2)+(3*4)+(2*0)+(1*0)=166
166 % 10 = 6
So 572924-00-6 is a valid CAS Registry Number.
InChI:InChI=1/C12H21NO4/c1-12(2,3)9(10(14)15)13-11(16)17-8-6-4-5-7-8/h8-9H,4-7H2,1-3H3,(H,13,16)(H,14,15)/t9-/m1/s1
572924-00-6Relevant articles and documents
Highly efficient carbamate formation from alcohols and hindered amino acids or esters using N, N′-disuccinimidyl carbonate (DSC)
Li, Hongmei,Chen, Cheng-Yi,Balsells Padros, Jaume
, p. 1454 - 1458 (2011/08/03)
A highly efficient and straightforward protocol to prepare carbamates from alcohols and hindered amino acids/esters mediated by N,N′-disuccinimidyl carbonate (DSC) in the presence of catalytic amount of pyridine is described. This method could be carried out under mild conditions in one pot, and a wide variety of carbamates were obtained in high yield with excellent purity. Georg Thieme Verlag Stuttgart - New York.
Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335)
Llinàs-Brunet, Montse,Bailey, Murray D.,Goudreau, Nathalie,Bhardwaj, Punit K.,Bordeleau, Josée,B?s, Michael,Bousquet, Yves,Cordingley, Michael G.,Duan, Jiamin,Forgione, Pat,Garneau, Michel,Ghiro, Elise,Gorys, Vida,Goulet, Sylvie,Halmos, Ted,Kawai, Stephen H.,Naud, Julie,Poupart, Marc-André,White, Peter W.
experimental part, p. 6466 - 6476 (2010/11/04)
C-Terminal carboxylic acid containing inhibitors of the NS3 protease are reported. A novel series of linear tripeptide inhibitors that are very potent and selective against the NS3 protease are described. A substantial contribution to the potency of these
INHIBITORS OF SERINE PROTEASES
-
Page/Page column 291-292, (2010/11/26)
The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease.